Elixir Medical's Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World's First Site-Specific Antithrombotic Therapeutic Compared to DES

DESyne BDS Plus system with site-specific antithrombotic therapeutic (TRx) significantly reduced the risk of TLF versus conventional drug-eluting stent through 12-months

Related Keywords

New Zealand ,Sao Paulo ,Sãpaulo ,Brazil ,Paris ,France General ,France ,United States ,Alexandran Nowbar ,Jamesp Howard ,Michael Foley ,Kui Hong ,Motasim Sirhan ,Xiaoqing Li ,Liza Chacko ,Darrelp Francis ,Ochen ,Dina Mahdi ,Sayan Sen ,Alexandre Abizaid ,Graham Cole ,Rasha Al Lamee ,Yuhao Su ,Yousif Ahmad ,Christopher Kane ,Christopher Rajkumar ,Centers For Disease ,Randomized Controlled Trial ,Randomized Clinical Trial ,Triple Drug Eluting Coronary Implant ,Eluting Coronary Stent System ,Disease Facts ,Disease Control ,Matthew Shun Shin ,Percutaneous Coronary Intervention ,Myocardial Infarction Stratified ,Unstable Coronary Artery Disease ,Randomized Controlled Trials ,Cardiovascular Quality ,Non Cardiac Surgery Early ,Percutaneous Coronary ,